MX389596B - Composiciones y métodos para el tratamiento de enfermedades de la mucosa nasal y paranasal con agonistas del receptor de acetilcolina de tipo nicotínico. - Google Patents

Composiciones y métodos para el tratamiento de enfermedades de la mucosa nasal y paranasal con agonistas del receptor de acetilcolina de tipo nicotínico.

Info

Publication number
MX389596B
MX389596B MX2018012439A MX2018012439A MX389596B MX 389596 B MX389596 B MX 389596B MX 2018012439 A MX2018012439 A MX 2018012439A MX 2018012439 A MX2018012439 A MX 2018012439A MX 389596 B MX389596 B MX 389596B
Authority
MX
Mexico
Prior art keywords
nasal
methods
acetylcholine receptor
nicotinic
diseases
Prior art date
Application number
MX2018012439A
Other languages
English (en)
Other versions
MX2018012439A (es
Inventor
Herrera Arturo Solis
Original Assignee
Herrera Arturo Solis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016901359A external-priority patent/AU2016901359A0/en
Application filed by Herrera Arturo Solis filed Critical Herrera Arturo Solis
Publication of MX2018012439A publication Critical patent/MX2018012439A/es
Publication of MX389596B publication Critical patent/MX389596B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A61N2005/0607—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen metodos de tratamiento y prevencion de condiciones de una membrana mucosa nasal o paranasal; los metodos incluyen administrar una composicion farmaceutica que incluye un agonista del receptor de acetilcolina de tipo nicotinico (nAChR), tal como (S)-(1-metil-2-pirrolidinil)-piridina, o una sal, analogo, precursor, o derivado farmaceuticamente aceptable del mismo; los metodos se pueden usar para tratar una amplia variedad de condiciones de la membrana mucosa nasal o paranasal, tal como congestion nasal y sangrados nasales.
MX2018012439A 2016-04-12 2017-04-12 Composiciones y métodos para el tratamiento de enfermedades de la mucosa nasal y paranasal con agonistas del receptor de acetilcolina de tipo nicotínico. MX389596B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2016901359A AU2016901359A0 (en) 2016-04-12 Application of Nicotine Compounds to Nasal Membranes
PCT/IB2017/000764 WO2017178897A2 (en) 2016-04-12 2017-04-12 Compositions and methods for treating paranasal mucosa diseases with nicotinic acetylcholine receptor agonists

Publications (2)

Publication Number Publication Date
MX2018012439A MX2018012439A (es) 2019-02-21
MX389596B true MX389596B (es) 2025-03-20

Family

ID=60042487

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012439A MX389596B (es) 2016-04-12 2017-04-12 Composiciones y métodos para el tratamiento de enfermedades de la mucosa nasal y paranasal con agonistas del receptor de acetilcolina de tipo nicotínico.

Country Status (15)

Country Link
US (1) US10639300B2 (es)
EP (1) EP3442583B1 (es)
JP (1) JP6770091B2 (es)
KR (1) KR102199560B1 (es)
CN (1) CN109069649A (es)
AU (1) AU2017250514B2 (es)
BR (1) BR122023020807A2 (es)
CA (1) CA3014725C (es)
ES (1) ES2984490T3 (es)
HK (1) HK1258883A1 (es)
MX (1) MX389596B (es)
NZ (1) NZ744942A (es)
PL (1) PL3442583T3 (es)
RU (1) RU2718061C1 (es)
WO (1) WO2017178897A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11096932B2 (en) * 2016-09-29 2021-08-24 The Uab Research Foundation Methods and compositions for increasing mucus clearance
CN116251080A (zh) * 2023-02-16 2023-06-13 杭州师范大学 茄尼醇在制备预防、治疗或缓解慢性疼痛药物中的应用
CN120078753A (zh) * 2023-12-01 2025-06-03 北京生命科技研究院有限公司 茄尼醇在制备预防和/或治疗皮炎的药物中的用途
EP4623920A4 (en) * 2024-02-16 2026-04-08 Catholic Univ Korea Ind Academic Cooperation Foundation Pharmaceutical composition comprising inferior nasal turbinate stem cells as the active ingredient for the prevention or treatment of secondary atrophic rhinitis

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8301659D0 (en) * 1983-01-21 1983-02-23 Leo Ab Smoking substitutes
GB9310412D0 (en) 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
MA23588A1 (fr) * 1994-06-23 1995-12-31 Procter & Gamble Traitement du besoin en nicotine et/ou du syndrome de manque lie au tabagisme
US6277855B1 (en) 2000-04-21 2001-08-21 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
US6596740B2 (en) * 2000-10-24 2003-07-22 Richard L. Jones Nicotine mucosal spray
HU224941B1 (en) 2001-08-10 2006-04-28 Bgi Innovacios Kft Phototerapy apparatus
US20040254146A1 (en) 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
ES2462545T3 (es) 2002-12-06 2014-05-23 The Feinstein Institute For Medical Research Un procedimiento para la determinación de un agonista colinérgico selectivo para un receptor alfa7 nicotínico
ES2321721T3 (es) 2003-09-08 2009-06-10 Mcneil Ab Formulaciones de nicotina y uso de las mismas.
RU2414461C2 (ru) 2004-07-15 2011-03-20 Юниверсите Лаваль Агонисты рецепторов никотина и способы их применения для лечения воспалительных заболеваний
BRPI0621650A2 (pt) 2006-05-08 2011-12-20 Arturo Solis Herrera composições farmacêuticas que induzem a liberação do alfa-msh endogênico a partir de células-tronco, e usos de uma substáncia ativa que induz a referida liberação e de alfa-msh sintetizado por qualquer meio
WO2008062453A2 (en) * 2006-09-25 2008-05-29 Nikki Nikhilesh Singh Composition containing nicotine base aromatic oils and alkyl salicylate for the delivery of nicotine base in vapour form
CL2008003507A1 (es) * 2007-11-26 2009-11-27 Neuroderm Ltd Composicion farmaceutica que comprende nicotina y un inhibidor de la desensibilizacion del receptor de acetilcolina nicotinico (nachr) opipramol; kit farmaceutico; dispositivo medico; y uso para tratar una enfermedad o trastorno del sistema nervioso central o periferico.
US9744375B2 (en) * 2010-08-05 2017-08-29 Allergia, Inc. Apparatus and methods for controlling and applying flash lamp radiation
KR102957402B1 (ko) * 2013-12-05 2026-04-24 쥴 랩스, 인크. 에어로졸 장치를 위한 니코틴 액제 및 그 방법
CN104706556A (zh) * 2015-03-31 2015-06-17 苏州维泰生物技术有限公司 抗过敏组合物及其在化妆品中的应用

Also Published As

Publication number Publication date
HK1258883A1 (zh) 2019-11-22
CA3014725A1 (en) 2017-10-19
JP6770091B2 (ja) 2020-10-14
ES2984490T3 (es) 2024-10-29
RU2718061C1 (ru) 2020-03-30
CA3014725C (en) 2020-09-22
KR102199560B1 (ko) 2021-01-07
BR122023020807A2 (pt) 2023-12-12
EP3442583A2 (en) 2019-02-20
AU2017250514A1 (en) 2018-08-23
EP3442583A4 (en) 2019-12-25
WO2017178897A3 (en) 2017-11-23
KR20180108821A (ko) 2018-10-04
PL3442583T3 (pl) 2024-08-19
CN109069649A (zh) 2018-12-21
NZ744942A (en) 2020-08-28
WO2017178897A2 (en) 2017-10-19
US20190111038A1 (en) 2019-04-18
MX2018012439A (es) 2019-02-21
EP3442583C0 (en) 2024-04-10
BR112018067718A2 (pt) 2019-01-08
JP2019511520A (ja) 2019-04-25
US10639300B2 (en) 2020-05-05
AU2017250514B2 (en) 2019-12-19
EP3442583B1 (en) 2024-04-10

Similar Documents

Publication Publication Date Title
MX2024010140A (es) Nuevos metodos.
MX394266B (es) Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
MX2019003173A (es) Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada.
ECSP19070369A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX375639B (es) Derivados de heterociclilos sustituidos como inhibidores de cdk
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
NI201900098A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX381313B (es) Derivados de benzimidazol como moduladores de ror-gamma
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
ECSP19083640A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112015017997A2 (pt) amidas de quinolina e quinazolina como moduladores de canais de sódio
BR112015018252A2 (pt) composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit
MX2015010829A (es) Compuestos terapeuticos y sus usos.
BR112017020039A2 (pt) composição farmacêutica, kit, método, processo para preparar uma composição e solução farmacêutica
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
NZ744942A (en) Compositions and methods for treating nasal and paranasal mucosa diseases with nicotinic acetylcholine receptor agonists
CL2023002871A1 (es) Composiciones nasales que comprenden alcaftadina
EA202090164A1 (ru) Изотретиноиновые перорально-слизистые композиции и способы их применения
MX2019006942A (es) Agonistas de receptores de oxitocina no peptidicos.
MX2015013115A (es) Nuevos regimenes de dosificacion de celgosivir para el tratamiento de dengue.
MX2017002476A (es) Composiciones y metodos para prevenir o tratar enfermedades, condiciones o procesos caracterizados por proliferacion de fibroblasto aberrante y matriz extracelular.
MX374938B (es) Un método para el tratamiento de trastornos del movimiento con befiradol.
MY189372A (en) Indole derivatives
MX2017011040A (es) Agente para el tratamiento de infeccion respiratoria.